Introduction
============

S-carboxymethylcysteine (carbocisteine or SCMC) is a mucoactive drug with in vitro free-radical scavenging and anti-inflammatory properties. Carbocisteine was first synthesized in the 1930s and became available for use as a mucoregulator in respiratory disease in the 1960s. A lack of consistency in data on clinical efficacy resulted in diminished use in the UK, and National Health System (NHS) formulary blacklisting in the 1980s. Throughout this time, prescribing of mucolytic/mucoactive agents for short- and long-term use remained common in Europe. However, a new understanding of the importance of exacerbation frequency in the progression of chronic obstructive pulmonary disease (COPD) and the role of systemic inflammation in the disease process, together with publication of several trials demonstrating positive effects of mucoactive drugs on exacerbation rates and quality of life, have rekindled interest in this family of drugs. There is increasing evidence that drugs commonly used for their mucoactive properties have diverse mechanisms of action, including significant anti-oxidant activity. In light of the well-established role of oxidative stress in the pathogenesis of COPD, it seems plausible that when these drugs are used over the long term they may modify the disease process. Carbocisteine became available by NHS prescription for chronic use in COPD once again in 2003.

Carbocisteine: pharmacology
===========================

Carbocisteine is available as an oral preparation both, as SCMC and its lysine salt (SCMC-Lys). The lysine group is cleaved on gastric absorption to form the active drug SCMC. Carbocisteine is a blocked thiol derivative of amino-acid; L-cysteine. The structure and mechanism of action of carbocisteine differs from other commonly available mucolytic drugs such as N-acetylcysteine (NAC) and erdosteine that bear free sulfhydryl (thiol) groups via which they split glycoprotein bonds in mucus.

Carbocisteine is well absorbed when taken orally, demonstrating one compartment open model kinetics thereafter. Peak serum concentrations are achieved at 1 to 1.7 hours and the plasma half-life is 1.33 hours. It achieves good penetration into lung tissue and bronchial secretions ([@b43-copd-3-659]; [@b8-copd-3-659]).

Approximately 30% to 60% of the drug is excreted unchanged in urine. Metabolic pathways are particularly complex with great inter-individual variation. They include acetylation, decarboxylation and sulfoxidation to produce inactive derivatives. Hepatic cytosolic sulfoxidation produces metabolites, which do not have the free-radical scavenging properties of the sulfide parent compound. Metabolism in this manner demonstrates a diurnal variation with less sulfoxidation occurring at night. There is also considerable variability in metabolism between individuals due to a genetic polymorphism in sulfoxidation capacity. Less efficient metabolism may result in increased exposure to the active parent compound and has been cited as one explanation for the inconsistent clinical response seen between individuals receiving the drug ([@b50-copd-3-659]; [@b46-copd-3-659]).

There has been interest in the selection of patients for therapy on the basis of their metabolic activity for many years. In current practice, response is established on clinical grounds after a trial period, and non-responders are instructed to discontinue the drug. It is unclear whether those with seemingly appropriate clinical indications for carbocisteine who do not experience an improvement with its initiation are active sulfoxidizers and whether they might respond to a higher dose or nocturnal dosing regimens.

There is a theoretical risk of gastric erosion in the context of alterations in the characteristics of gastric mucus with all mucolytic agents. Carbocisteine is, therefore, contraindicated in active gastric ulceration. No significant toxicity has been reported either in animal models or following prolonged use in humans, and no drug interactions have been identified. Mild side-effects (largely gastric discomfort) are occasionally reported, eg, 1.8% of patients in the treatment arm of one large study ([@b2-copd-3-659]). Fixed drug eruption has also been infrequently associated with long-term prescribing of carbocisteine. It has been proposed that exposure to metabolic products, such as thiodiglycolic acid, may be responsible for this response. Thiodiglycolic acid is produced in greater concentration in poor sulfoxidizers, and so these reactions (ie, cutaneous) may be more common in this patient group ([@b45-copd-3-659]).

Dose regimens for carbocisteine vary internationally, ranging from 750 mg twice daily to 4.5 g once daily. There is little evidence to advocate one particular dosing regimen, although (as previously discussed) nocturnal administration may achieve higher concentrations of the active compound.

Targets for carbocisteine in COPD: natural history and the role of oxidative stress
===================================================================================

COPD manifests as airway obstruction that is not fully reversible and deteriorates over time, at a rate greater than that seen with advancing age. The underlying disease process affects both the airways and interstitial lung tissue. Airway abnormalities include smooth muscle hypertrophy, mucus accumulation, wall thickening with neutrophil and inflammatory infiltrate, and an increase in number and size of goblet cells. The accompanying clinical syndrome of chronic bronchitis frequently co-exists with emphysema (the interstitial component) under the umbrella term of COPD. Central to the development and progression of the disease is a process of oxidative stress and proteinase--antiproteinase imbalance that frequently becomes self perpetuating ([@b39-copd-3-659]).

Oxidants derived from cigarette smoke and other environmental pollutants, in addition to those produced as a result of neutrophilic inflammation, inactivate antiproteinases (particularly α1-antitrypsin). This results in uncontrolled elastase activity and pulmonary tissue destruction, both by direct toxicity to protein and lipid structures and via the up-regulation of interleukin-8 (IL-8) activity. Elastase promotes the conversion of endogenous pulmonary xanthine dehydrogenase to xanthine oxidase, which acts on purine substrates and molecular oxygen to produce superoxide; a process that is central to oxidative stress in many inflammatory lung diseases.

Oxidants also exert a directly toxic effect on the structures of the lung, impair cilial activity and increase mucus production by goblet cells ([@b1-copd-3-659]; [@b22-copd-3-659]).

Ongoing neutrophil and free-radical induced inflammation, along with the accumulation of tenacious mucus and airway remodeling with smooth muscle hyperplasia, results in increasing airflow limitation and creates an environment conducive to bacterial colonization. This, in itself, contributes to persistent inflammation and to neutrophil and alveolar macrophage recruitment to the airways, and is associated with a greater severity of airflow obstruction ([@b44-copd-3-659]; [@b52-copd-3-659]).

There is increasing evidence that COPD is a disease of systemic inflammation and that deterioration in parameters other than forced expiratory volume in one second (FEV~1~) predict outcomes with greater sensitivity. Muscle dysfunction, both peripheral and diaphragmatic, is an important contributor to decline in patients with COPD. Quadricep strength and maximum inspiratory pressure generation have been shown to be predictors of mortality in moderate and severe COPD ([@b47-copd-3-659]; [@b34-copd-3-659]). Elevated markers of oxidative stress have been demonstrated in the diaphragms of patients with severe COPD, and levels of protein oxidation have a negative correlation with respiratory muscle strength ([@b7-copd-3-659]). Peripheral muscles, particularly of the lower limbs, are also exposed to increased levels of both oxidative and nitrosative stress ([@b6-copd-3-659]). Both muscle groups demonstrate shifts in fiber type and atrophy that can be partially attributed to chronic inflammation and free-radical activity ([@b34-copd-3-659]).

Outcomes of relevance to disease progression in COPD have only been defined in recent years. Older studies tended to focus on lung function, a measure now thought to be a less useful marker of disease. Outcomes for the results of clinical interventions in COPD that are now thought to be relevant include: exacerbation rates; days of illness and hospital bed days; rate of lung function and exercise tolerance decline; all cause mortality; and improvement in health-related quality of life.

Acute exacerbations of COPD often occur in response to bacterial or viral infection and are recognized as deterioration in a patient's respiratory symptoms, frequently requiring additional treatment. Exacerbations incur significant healthcare costs and contribute to decline in patients' health-related quality of life ([@b41-copd-3-659]). Donaldson et al first established that more frequent exacerbations of COPD are associated with a greater rate of decline in lung function parameters ([@b20-copd-3-659]). It is recognized that some COPD patients experience frequent exacerbations, yet in others the disease takes a more stable course. Following many exacerbations, clinical and physiological state fails to return to baseline, and systemic inflammation continues on at a heightened level ([@b42-copd-3-659]).

Clinical application of mucoactive drugs in COPD
================================================

The 2006 Cochrane meta-analysis of mucolytic agents for COPD included 26 placebo-controlled, randomized clinical trials (RCTs) involving 7,335 patients ([@b36-copd-3-659]). SCMC, SCMC-Lys and SCMC-sobrerol were included in only 3 of the trials, comprising a total of 486 subjects. The majority of the evidence included in the meta-analysis concerned NAC, the most widely used mucolytic agent internationally. The review concluded that there was evidence for a statistically significant reduction in the number of exacerbations per patient with long-term use (greater than 2 months) of oral mucolytics, of the order of 20% (0.5 exacerbations per patient per year). Overall, days of disability were reduced to a greater extent in the sub-set of intervention groups where this outcome was reported. Patients receiving mucolytics were more likely to experience no exacerbations than those receiving placebo, with a number needed to treat (NNT) of 6. There is variability between the studies in reported changes in lung function parameters, which precludes a firm conclusion on the effect of mucolytics on spirometric parameters. Few of the studies included had measured health-related quality of life using validated tools and only one, concerning the use of erdosteine, demonstrated a significant improvement with the drug compared with placebo ([@b33-copd-3-659]). The Cochrane review did not reveal a significant variation in outcome measures between different mucolytic agents and no serious adverse events were reported within the pooled data. The authors state that: "it is unlikely that the magnitude of the impact on exacerbation rates reported in the review will translate to COPD patients receiving current standard care". Firstly, it is assumed that many of the study patients will not have received inhaled corticosteroids (ICS), which were not in routine use in COPD prior to 1990, although this information is not specifically provided for many of the trials. Secondly, a great proportion of the studies were conducted over the winter period, during which exacerbation rates peak. The impact of mucolytic agents on the lower summer exacerbation rates is likely to be less impressive. The 2006 Cochrane review also raised the possibility of economic value in restricting mucolytic use exclusively to the winter months.

Supported by the National Institute for Health and Clinical Excellence (NICE) and British Thoracic Society (BTS) guidelines, mucolytic agents are currently in use selectively in COPD patients. The single available study on the cost-effectiveness analysis of mucolytics (specifically NAC) in COPD does not support prescribing in unselected patients with COPD ([@b24-copd-3-659]). At this time, there is a greater weight of evidence for their use in patients who exacerbate frequently and produce sputum chronically. Patients with significant symptoms related to sputum production, but who have mildly obstructive spirometry and therefore do not fulfil criteria for ICS, are likely to have the most to gain in terms of exacerbation reduction. This represents a small minority of COPD patients presenting to medical services. In practice, patient-reported improvement in symptoms related to sputum clearance and infective exacerbations is used to guide continuation with a mucolytic agent. In the clinical setting, most physicians are reluctant to temporarily suspend (ie, over the summer months) a safe intervention that has been associated with symptomatic relief.

Available mucolytic agents have been shown to have additional anti-inflammatory and anti-oxidant activities. In theory, therefore, they offer the potential to modify the disease, beyond aiding sputum clearance and reducing exacerbation rates. Clinical evidence to this effect would support their broader application in COPD. The Bronchitis Randomised on N-acetylcysteine Cost-Utility Study (BRONCUS) sought to examine aspects of this hypothesis in an RCT comparing NAC 600 mg daily with placebo, in 523 patients over a 3-year period ([@b18-copd-3-659]). The study, the longest of its kind, demonstrated no significant differences in lung function decline, exacerbation rates or deterioration in health status between patients in the treatment and placebo arms, except in the subgroup of patients not receiving ICS as standard management. No sufficiently long-term studies have been conducted with carbocisteine to specifically examine modification of disease progression or mortality as an outcome measure.

In vitro, ex vivo and in vivo properties of carbocisteine
=========================================================

Mucoregulation and effects on sputum clearance
----------------------------------------------

The viscoelastic properties of bronchial mucus are determined by glycoproteins (namely fucomucins, sialomucins and sulfomucins). Higher concentrations of fucomucins are found in the sputum of patients with COPD ([@b31-copd-3-659]).

Carbocisteine resets the balance between sialomucins and fucomucins (increasing concentrations of the former and reducing the latter) probably via the intracellular stimulation of sialyl transferase activity ([@b26-copd-3-659]). It is not thought to act on the structure of mucus once secreted into the airways in contrast to true mucolytic agents such as NAC. There is evidence from animal models that carbocisteine increases chloride transport across the airway epithelium and this may also contribute to its mucoregulatory action ([@b17-copd-3-659]).

Several studies have demonstrated a reduction in measured sputum viscosity as early as 4 days after treatment initiation ([@b21-copd-3-659]; [@b11-copd-3-659]). Braga et al examined the sputum viscosity and elasticity of 53 patients with chronic bronchitis when treated with 4.5 g of carbocisteine daily for 5 days compared with placebo ([@b10-copd-3-659]). There were significant reductions in both sputum characteristics with carbocisteine in patients with initial sputum viscosity and elasticity above the mean value previously established in similar patient groups. There is also in vivo and in vitro evidence of increased mucociliary clearance velocity with carbocisteine, particularly in patients with slow clearance before treatment ([@b30-copd-3-659]; [@b11-copd-3-659]). This, apparently selective, action supports a mucoregulatory mechanism and, in clinical practice, supports the careful selection of patients for treatment with carbocisteine when it is prescribed for a possible symptomatic benefit associated with enhanced sputum clearance. Significantly, there are, also negative studies examining changes in sputum characteristics, in which different laboratory methods were employed ([@b49-copd-3-659]; [@b23-copd-3-659]). One explanation for this inconsistency is small study sample sizes combined with the inter-individual variability in response to the drug seen in clinical practice. However, there is also a lack of evidence correlating measurable mucoactive, drug-induced changes in sputum characteristics with clinical benefit. It is therefore not clear, when benefit is demonstrated, whether the mucoactive component to drug action should be credited. It should also be noted that in vitro studies of sputum viscosity are difficult to standardize and a commonly accepted methodology has not been derived.

There is evidence that carbocisteine increases the penetration of amoxicillin into bronchial secretions of patients with bacterial exacerbations of chronic bronchitis when the drugs are used concomitantly. This effect is probably due to the alterations in glycoprotein composition of sputum ([@b9-copd-3-659]). Improving antibiotic delivery to the site of bacterial infection may have a valuable effect, but the specific clinical implications of this finding on acute infective exacerbations have not been fully studied.

Actions on damaged epithelium and cough sensitivity
---------------------------------------------------

Evidence from animal models of respiratory epithelial repair demonstrates that carbocisteine reverses neutral endopepsidase levels and reduces cough sensitivity (but not methacholine-induced bronchoconstriction) in rodents with antigen-damaged tracheal epithelium in a dose-related manner ([@b29-copd-3-659]). Neutral endopeptidase is a cell membrane bound enzyme that modulates tachykinin-induced potentiation of: cholinergic motor transmission; smooth muscle contraction; mucus secretion; cough, and increases in vascular permeability in the airways. It has been repeatedly demonstrated in both human and animal studies that neutral endopeptidase levels are reduced in the presence of respiratory epithelial injury and associated bronchial hyper-responsiveness ([@b15-copd-3-659]; [@b16-copd-3-659]). Ishiura et al performed a double-blind, placebo-controlled, cross-over trial that illustrated a significant reduction in cough sensitivity to inhaled capsaicin (a C-fiber type bronchial cough receptor stimulator) in asthma patients following a 4-week course of carbocisteine ([@b27-copd-3-659]). The investigators proposed that an increase in neutral endopeptidase levels could explain this drug effect and that carbocisteine may have a role in the treatment of cough-variant asthma and other inflammatory airways disease in which intractable cough is a feature.

Action on respiratory pathogens
-------------------------------

Attachment of pathogens to the respiratory epithelial cell surface is the first step in the development of acute respiratory tract infections, most of which are initiated by colonization of the pharynx.

One possible mechanism by which carbocisteine has the potential to reduce bacterial respiratory tract infections in COPD is the inhibition adherence of pathogenic bacteria to cells. In vitro studies have demonstrated a significant reduction in adherence of *Moraxella catarrhalis* to the pharyngeal epithelial cells, of both healthy subjects and those with chronic bronchitis treated with carbocisteine, when compared with placebo ([@b53-copd-3-659]). Similarly, attachment of *Streptococcus pneumoniae* to pharyngeal epithelial cells taken from healthy subjects has been shown to be reduced by direct in vitro treatment of the cells with carbocisteine ([@b13-copd-3-659]). It has been proposed that disruption of bacterial receptor sites on the epithelial surface and within mucus may explain these findings.

Rhinoviruses are associated with exacerbations of COPD. They increase oxidative stress and the production of inflammatory mediators. Intercellular adhesion molecule-1 (ICAM-1) is required for entry of rhinovirus ribonucleic acid (RNA) into cellular endosomes. Circulating ICAM-1 is present in greater concentrations in COPD and may have a role in neutrophil recruitment and retention in the lung, in addition to increasing susceptibility to viral respiratory tract infections ([@b40-copd-3-659]). Carbocisteine reduces expression of ICAM-1 and has been associated with a reduction in frequency of common colds and associated exacerbations in COPD patients ([@b48-copd-3-659]).

Anti-oxidant and anti-inflammatory activity
-------------------------------------------

As discussed, airway inflammation and oxidative stress due to inflammation, infection, inhaled environmental pollutants and (particularly) cigarette smoke plays a significant part in the development and progression of COPD.

Animal studies have demonstrated the anti-inflammatory action of carbocisteine in models of induced pulmonary inflammation involving several different cytokine profiles. Oral pre-treatment with SCMC-Lys appears to attenuate neutrophil recruitment in acute IL-1β-induced airway inflammation and neutrophil, macrophage and eosinophil migration to the pleural space in carrageenan induced pleurisy ([@b3-copd-3-659]). Administration of carbocisteine to rats with sulfur dioxide-induced airway inflammation attenuates the secretion of abnormal mucous glycoproteins and reduces inflammatory cells, free radical and elastase activity in their bronchoalveolar lavage (BAL) fluid ([@b28-copd-3-659]).

Carbocisteine has been shown to have relevant in vitro free-radical scavenging properties. NAC is recognized as a mucolytic agent with anti-oxidant behavior that is exerted via its free thiol group to form NAC disulfide. In contrast, carbocisteine does not carry a free thiol group but its thioether group can be oxidized by reactive oxygen species to form the sulfoxide by-product; however its anti-oxidant mechanism is not yet fully understood. Pinamonti et al conducted a series of experiments in 3 oxygen radical-producing systems ([@b35-copd-3-659]). The experiments demonstrated that the addition of carbocisteine to the BAL fluid of stable COPD patients markedly reduced lymphocyte DNA destruction and reduced oxidative activity (measured as reduced cytochrome c concentration) of the solution in a dose-dependent manner. Free radical damage to deoxyribonucleic acid (DNA) in ultrasound-treated human serum was also reduced by the addition of carbocisteine. Finally, the concentration of xanthine oxidase products (superoxide and uric acid) in the supernatant of endothelial cells cultured with elastase was significantly reduced by the addition of carbocisteine to the culture.

Activated neutrophils produce a range of free radicals, with hydroxyl radical (OH^−^) and hypochlorus acid (HOCl) being the most potent in terms of tissue injury. HOCl in particular oxidizes the methionyl residues of α1-antitrypsin, inactivating it and resulting in uncontrolled neutrophil elastase action. Intracellular production of OH^−^ is implicated in IL-8 production that, in turn, has a role in the up-regulation of protease activity ([@b19-copd-3-659]). Brandolini et al examined the free-radical scavenging capacity and its mechanism of SCMC-Lys in cell-free and cellular solutions ([@b12-copd-3-659]). In the cell-free studies, SCMC-lys demonstrated a potent, concentration-dependent reducing effect on NaOCl and HOCl, with resultant oxidation of the drug's thioether group to form the sulfoxide (S--CMC = O). In this model, the reducing capacity of SCMC-Lys was equal to that of glutathione (the chief endogenous anti-oxidant). A SCMC-Lys concentration-dependent reduction of HOCl-mediated inhibition of α1-antitrypsin was also demonstrated. In the cellular studies, an equally potent free-radical scavenging action was demonstrated with OH^−^ when a solution containing neutrophils and deoxyribose was combined with SCMC-Lys, which inhibited the selective oxidation of deoxyribose by neutrophil hydroxyl radicals. Finally, SCMC-Lys was shown to inhibit both paraquat- and IL-1β-induced IL-8 production by human peripheral blood mononuclear cells.

8-isoprostane is produced by the reaction of oxygen radicals with arachidonic acid and other endogenous polyunsaturated fatty acids. It can be measured in breath condensate as a marker of oxidative stress in the lung. Exhaled 8-isoprostane is significantly elevated in stable, and to a greater extent exacerbating COPD ([@b32-copd-3-659]; [@b14-copd-3-659]). Carpagnano et al demonstrated a significant reduction in both exhaled 8-isoprostane and pro-inflammatory cytokine, IL-6, in patients with COPD treated with SCMC-Lys for a 6-month period, providing an in vivo translation for the wealth of in vitro evidence that the drug has anti-inflammatory and anti-oxidant properties.

Long-term use of carbocisteine and SCMC-Lys in COPD
===================================================

Clinical trial data on the use of carbocistiene in COPD are summarized in [Table 1](#t1-copd-3-659){ref-type="table"}.

Several small studies conducted prior to 1990 compared 2.25 g to 3.00 g carbocisteine daily with placebo in chronic bronchitis, examining the outcome measures of lung function, sputum characteristics and symptom scores ([@b5-copd-3-659]; [@b21-copd-3-659]; [@b37-copd-3-659]; [@b25-copd-3-659]). Reported impact on lung function parameters is variable, but effect on the more subjective measures of cough and dyspnea resolution, and on increased sputum clearance is more consistently positive. These studies did not use well-validated outcome measures, and duration of carbocystiene administration varied from 10 days to 6 months, making it difficult to draw general conclusions about their clinical relevance.

Exacerbation rate has been demonstrated to have a significant impact on disease progression and health-related quality of life in COPD ([@b41-copd-3-659]). It therefore represents a relevant and definable outcome measure in clinical trials.

Four systematically-blinded and randomized studies comparing SCMC/SCMC-Lys with placebo and using exacerbations as the primary outcome measure have been reported. [@b2-copd-3-659] conducted their study over a 6-month period during the winter. Their 662 patients had baseline lung function suggestive of mild-to-moderate COPD. ICS were not excluded, but the proportion of patients in each group on ICS as standard treatment is of the placebo group was not stated. The baseline FEV~1~ significantly lower than that of the treatment group. Patients who received carbocisteine were significantly more likely to remain exacerbation free than the placebo group (χ^2^ 13.98, p = 0.001). A large proportion of all study patients remained exacerbation-free (54.0% in the placebo group compared with 70.4% in the continuous SCMC-Lys treatment group). Mean time to first exacerbation was significantly prolonged in the treatment group (96 days compared with 130 days). There was a statistically significant reduction in mean days of acute respiratory illness per patient (3.8 ± 7.4 days compared with 6.7 ± 9.7 days) with an equivalent reduction in days of antibiotics required. There were no statistically significant effects of intermittent treatment with carbocisteine compared with results in patients receiving placebo. The total number of exacerbations during the study period for each group was not reported ([@b2-copd-3-659]).

An earlier double-blind, parallel-group study carried out in the UK examined the impact of 750 mg carbocisteine 3 times daily compared with placebo on peak flow and exacerbation rate in 109 patients with chronic bronchitis (Medical Research Council defined) over 6 winter months ([@b25-copd-3-659]). The baseline characteristics of the groups are reported to be well matched, although no specific baseline statistics (including drug therapy at trial entrance) are listed. There was no demonstrable significant difference in exacerbation rate between treatment groups.

In a Japanese trial, Yasuda et al compared carbocisteine 1.5 g daily with placebo in 156 patients with COPD over a 12-month period ([@b51-copd-3-659]). The subjects tended to have mild COPD, and the 2 trial groups demonstrated no significant differences in baseline characteristics. Of note, no patients received ICS or oral corticosteroids during the study. There was a statistically significant reduction in the number of common colds (as defined by a validated 10-point symptom scoring system) in the carbocisteine group (1.69 ± 0.18 compared with 3.14 ± 0.35, relative risk \[RR\] 0.40 \[95% CI 0.20--0.80\]). The exacerbation rate was also significantly reduced in the treatment group: RR 0.30 (95% CI 0.20--0.70). Mean exacerbations per patient per year were 0.54 ± 0.11 in the treatment group compared with 1.38 ± 0.20 for placebo.

Most recently, the well-powered and systematically conducted Chinese PEACE study has demonstrated a clinically and statistically significant reduction in exacerbation rates in patients with moderate-to-severe COPD receiving carbocisteine over a 12-month period compared with placebo. A mean reduction of 0.34 exacerbations per patient per year was recorded in the treatment group (receiving 500 mg carbocisteine 3 times a day for a 12-month period) compared with placebo ([@b54-copd-3-659]). Reduction in the rate of exacerbations only became significant after 6 months of treatment. Quality of life measures were also significantly improved at 12 months, consistent with the reduction in exacerbations. The study demonstrates the value of long-term carbocisteine in Chinese patients with COPD, but these results cannot be directly applied to European populations. Routine treatment for COPD in China includes the early prescription of methyl-xanthines and minimal use of ICS. In the study group, only 16.7% received ICS and, although this subgroup also demonstrated benefit from carbocisteine, it is likely that far lower-dose corticosteroids were in use than those routinely prescribed in Europe.

Conclusions
===========

Carbocisteine exhibits a wide range of in vitro and in vivo anti-inflammatory and anti-oxidant activities in both human and animal models. In certain circumstances, it may diminish inflammatory cell recruitment to the airways, attenuate endothelial injury and associated cough sensitivity, and act as a potent, free-radical scavenger. These actions, in parallel with its mucoregulatory function, have theoretical relevance to pathogenic processes in COPD and other inflammatory airways disease. Clinical studies of carbocisteine in COPD examining the outcome measures of exacerbation rate and lung function parameters have produced heterogeneous results, reflecting those from studies with other mucolytic agents. Historically, trials have selected cohorts of patients with mild-to-moderate COPD, and there is circumstantial evidence that the impact of mucolytic and anti-oxidant agents is greater in patients who are not receiving ICS as standard management -- an increasingly small group. There has not yet been a trial specifically focused on carbocisteine of adequate duration to answer questions about its direct impact on disease progression or survival in COPD. Results from the BRONCUS concerning NAC were inconclusive when these outcomes were considered ([@b18-copd-3-659]).

Currently, the place for carbocisteine in COPD remains as a well-tolerated treatment with a favorable safety profile that provides symptomatic relief to some patients with sputum production, and that may reduce exacerbation rates via a range of mechanisms. Many uncertainties about carbocisteine remain. These include the relative clinical importance of its numerous mechanisms of action, appropriate patient selection and optimum dosing regimens (particularly to exploit the drug's anti-oxidant and anti-inflammatory activities). The majority of the evidence for carbocisteine's action is extrapolated from in vitro studies. To date, there are limited data from large randomized trials examining the effect of the addition of carbocisteine to existing treatment regimens, and so use of mucolytics is still largely based on clinical judgement and observation of symptomatic benefits in selected patients.
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Summary of some of the clinical trial data published on carbocisteine (SCMC)

  Reference                                                      Study design                                       Diagnostic category                 Mean baseline FEV~1~ (L/sec)   Study size   Duration    Drug administration                         Outcomes                                                  Results
  -------------------------------------------------------------- -------------------------------------------------- ----------------------------------- ------------------------------ ------------ ----------- ------------------------------------------- --------------------------------------------------------- -----------------------------------------------------------------------
  [@b4-copd-3-659]                                               Double-blind RCT                                   Chronic bronchitis                  SCMC 43.8% ± 3.6               n = 30       10 days     750 mg SCMC syrup tds vs bromhexine syrup   Increased sputum volume                                   C = B
                                                                                                                                                        Bromhexine 46.3% ± 4.9                                                                              Increased sputum 'pourability'                            C = B
  [@b4-copd-3-659]                                               Single-blind, cross-over study                     Chronic bronchitis (MRC criteria)   PEFR 148 ± 23 (L/min)          n = 30                                                               FEV~1~/PEFR                                               C = B (no change)
  [\#](#tfn2-copd-3-659){ref-type="table-fn"}[@b21-copd-3-659]   Double-blind RCT                                   Chronic bronchitis                  1.46 L                         n = 82       3 months    15 mL 5% SCMC syrup tds vs placebo          Reduction in dyspnea                                      C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
  [@b38-copd-3-659]                                              Double-blind RCT                                   Chronic bronchitis (MRC criteria)   Not stated                     n = 20                                                               Sputum volume                                             C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
  [@b25-copd-3-659]                                              Double-blind, parallel-group, study                Chronic bronchitis (MRC criteria)   PEFR 230 L/min                 n = 109                                                              Reduction in cough frequency and severity                 C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
  [@b2-copd-3-659]                                               Double-blind, multicenter, parallel-group, trial   Chronic bronchitis (MRC criteria)   SCMC 4.6 ± 1.9                 n = 662                                                              Ease of expectoration                                     C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                        Placebo 3.3 ± 1.5                                                                                   Improvement in incapacity                                 C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
  [@b48-copd-3-659]                                              RCT                                                COPD FEV~1~/FVC \<70%               SCMC 1.37 ± 0.07               n = 142      3 months    3 g SCMC syrup daily vs placebo             Sputum volume                                             C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                        Placebo 1.2 ± 0.06                                                                                  Reduction in sputum viscosity                             C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
  [†](#tfn6-copd-3-659){ref-type="table-fn"}[@b51-copd-3-659]    Double-blind RCT                                   COPD                                61.5% ± 2.2                    n = 156                                                              Reduction in dyspnea                                      C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
  [‡](#tfn7-copd-3-659){ref-type="table-fn"}[@b54-copd-3-659]    Double-blind RCT                                   COPD (GOLD criteria)                SCMC 43.93% ± 15.4             n = 709                                                              Increase in FEV~1~                                        C \> p[\*\*](#tfn4-copd-3-659){ref-type="table-fn"}
                                                                                                                                                        Placebo 45.1% ± 15.23                       2 weeks     1 g SCMC tds vs placebo                     Reduction in FEV~1~/VC ratio                              p \> C[\*\*](#tfn4-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Other measures of airway obstruction (MEFR 25% and 50%)   NS
                                                                                                                                                                                                                                                            Sputum viscosity (increased)                              C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Improved clinical status                                  C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                    6 months    750 mg SCMC tablets tds vs placebo          Increase in PEFR at 1,2,3 and 5 months                    C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Increase in PEFR at 4 and 6 months                        NS
                                                                                                                                                                                                                                                            Exacerbation rate                                         NS
                                                                                                                                                                                                    6 months    2.7 g SCMC daily vs placebo                 Patients with no exacerbations                            C \> p[\*\*\*](#tfn5-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Time to first exacerbation                                C \> p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Mean days of acute respiratory illness                    C \< p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Mean days of antibiotic treatment                         C \< p[\*](#tfn3-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                    12 months   500 mg SCMC tds vs usual care               Number of common colds                                    C \< p[\*\*](#tfn4-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Number of exacerbations                                   C \< p[\*\*](#tfn4-copd-3-659){ref-type="table-fn"} (RR 0.37)
                                                                                                                                                                                                                                                            Improvement in QoL (SGRQ)                                 C \> p[\*\*](#tfn4-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Change in FEV~1~                                          C = p (no change)
                                                                                                                                                                                                    12 months   1.5 g SCMC daily vs placebo                 Number of common colds                                    C \< p[\*\*](#tfn4-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Number of exacerbations                                   C \< p[\*\*](#tfn4-copd-3-659){ref-type="table-fn"} (RR 0.4)
                                                                                                                                                                                                    12 months   500 mg SCMC tds vs placebo                  Number of exacerbations                                   C \< p[\*\*](#tfn4-copd-3-659){ref-type="table-fn"} (risk ratio 0.75)
                                                                                                                                                                                                                                                            Improvement in QoL (SGRQ)                                 C \> p[\*\*\*](#tfn5-copd-3-659){ref-type="table-fn"}
                                                                                                                                                                                                                                                            Change in FEV~1~                                          C = p (no change)

**Abbreviations:** C, carbocisteine (SCMC); Bm, bromhexine syrup; FEV~1~, forced expiratory volume in one second; MEFR, maximum expiratory flow rate; MRC, Medical Research Council; PEFR, peak expiratory flow rate; QoL, quality of life; RCT, randomized controlled trial; SGRQ, St George's Respiratory Questionnaire; tds, 3-times daily; VC, vital capacity; L/sec, liters per second; L/min, liters per minute.

**Notes:** nebulized water produced equal results to SCMC.

p \< 0.05

p \< 0.01

p \< 0.001; NS, no statistically significant difference;

Inhaled or oral corticosteroids not permitted

Oral corticosteroids at trial entry not permitted.16.7% of trial patients on ICS.
